Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: A consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages 352-358

  Marchetti, Antonio ^a   Ardizzoni, Andrea ^b   Papotti, Mauro ^c   Crinò, Lucio ^d   Rossi, Giulio ^e   Gridelli, Cesare ^f   Barberis, Massimo ^g   Maiorano, Eugenio ^h   Normanno, Nicola ⁱ   Taddei, Gian Luigi ^j   Scagliotti, Giorgio ^c   Clemente, Claudio ^k   Pinto, Carmine ^l  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Perugia Hospital   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f S G MOSCATI HOSPITAL   (Italy)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h UNIVERSITY OF BARI   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k Sant'Ambrogio Clinical Institute   (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Anaplastic lymphoma kinase gene rearrangements; Guidelines; Non small cell lung cancer; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ITALY; LUNG NON SMALL CELL CANCER; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84874104032     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827d5280     Document Type: Article

References (54)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101: 13306-13311.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448: 561-566.
5. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131: 1190-1203.
6. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68: 4971-4976.
7. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription- PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14: 6618-6624.
8. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15: 3143-3149.
9. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14: 4275-4283.
10. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 2008;99: 2349-2355.
11. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008;10: 298-302.
12. Wong DW, Leung EL, So KK, et al.; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115: 1723-1733.
13. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4- ALK. J Clin Oncol 2009;27: 4247-4253.
14. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22: 508-515.
15. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17: 889-897.
16. Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76: 403-409.
17. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9: 188.
18. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68: 3389-3395.
19. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1): 3314-3322.
20. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67: 4408-4417.
21. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-1703.
22. Camidge DR, Bang YJ, Kwk EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29:Abstract 2501.
23. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12: 1004-1012.
24. U.S. Food and Drug Administration. FDA labeling information - Xalkori. [FDA Web site]. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/202570s000lbl.pdf. Accessed August 2011.
25. European Medicines Agency. Committee for Medicinal Products for Human Use. EMA Initial authorization - Xalkori. [EMA Web site]. 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Summary-of-opinion- Initial-authorisation/human/002489/WC500130138.pdf. Accessed August 2011.
26. Crinò L. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29:Abstract 7514.
27. National Comprehensive Cancer Network. NCCN Flash Update: NCCN Guidelines Updated. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
28. Lozano MD, Labiano T, Zudaire MI, et al. Usefulness of cytological samples (CS) for the assessment of ALK rearrangements in non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30:Abstract e18008.
29. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7: 348-354.
30. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced nonsmall cell lung cancer patients. Lung Cancer 2012;77: 288-292.
31. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6: 459-465.
32. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6: 466-472.
33. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011;9: 1335-1341.
34. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15: 5216-5223.
35. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35: 1226-1234.
36. Popat S, Gonzalez D, Min T, et al. ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer 2012;75: 300-305.
37. Yokota K, Sasaki H, Okuda K, et al. KIF5B/RET fusion gene in surgicallytreated adenocarcinoma of the lung. Oncol Rep 2012;28: 1187-1192.
38. Sen B, Peng S, Tang X, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 2012;4: 136ra70.
39. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12: 175-180.
40. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29: 3574-3579.
41. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6: 244-285.
42. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000;36: 8-16.
43. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26: 767-773.
44. Wu M, Wang B, Gil J, et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 2003;119: 696-702.
45. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15: 415-420.
46. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34: 1805-1811.
47. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35: 15-25.
48. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol 2011;6: 1190-1199.
49. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012;25: 405-415.
50. Marchetti A, Normanno N, Pinto C, et al.; AIOM - SIAPEC-IAP; Italian Association of Medical Oncology; Italian Society of Anatomic Pathology and Diagnostic Cytopathology. Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 2010;102: 119-126.
51. Pirker R, Herth FJ, Kerr KM, et al.; European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5: 1706-1713.
52. Vysis ALK Break Apart FISH Probe Kit datasheet. Available at: http://www.abbottmolecular.com/static/cms-workspace/pdfs/US/Vysis-ALK- FISH-Probe-Kit-PI.pdf. Accessed August 2011.
53. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012;136: 796-803.
54. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136: 266-274.